medigraphic.com

2014, Number 5

<< Back Next >>

Cir Cir 2014; 82 (5)

Isolated splenic metastases from cervical cancer: A rare entity

Villalón-López JS, Souto-del Bosque R, Montañez-Lugo JI, Chávez-González B

Language: Spanish
References: 20
Page: 556-562
PDF size: 485.76 Kb.


ABSTRACT

Background: Splenic metastases from solid tumors are a rare event with an incidence of only 2.9% to 9%. Splenic metastases from cervical cancer are a rare entity. Only a few cases have been reported of isolated spleen metastases from cervical cancer.
Clinical case: We present the case of a 76-year-old woman with moderately differentiated endocervical adenocarcinoma with stromal and endocervical invasion. Clinical stage was Ib1 and CA- 125 values of 150 U. She was managed with hysterectomy and pelvic lymphadenectomy. She received pelvic radiotherapy (45 Gy) followed 24 Gy of brachytherapy. Two years later she presented with abdominal pain. Abdominal computed tomography showed two splenic parenchymal lesions without disease in the remainder of the abdominal cavity and chest with a CA-125 of 2,733 U. The patient is submitted to splenectomy. Histopathology demonstrates splenic metastases of well-differentiated adenocarcinoma from the endocervix. Immunohistochemical stain showed positivity from carcinoembryonic antigen; estrogen and progesterone receptors are negative. CA-125 level 8 weeks after surgery was 16 U/ml. The patient received six cycles of adjuvant chemotherapy with paclitaxel and cisplatin. At 12 months follow-up the patient is alive and without evidence of tumor activity.
Conclusions: The spleen is an uncommon site of metastasis. Splenectomy is considered the appropriate treatment in order to avoid complications such as splenic rupture and splenic vein thrombosis as well as to improve pain control from splenomegaly. Twelve months after surgery our patient is alive and without evidence of tumor activity.


REFERENCES

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893-2917.

  2. Siegel R, Naishadham D, Jemal A. Cancer statistics 2013. Ca Cancer J Clin 2013;63(1):11-30.

  3. Perfil Epidemiológico de los Tumores Malignos en México. Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. (consultado el 15 marzo 2013). Disponible en http://www.dgepi.salud.gob.mx/2010/PDFS/ PUBLICACIONES/MONOGRAFIAS/PEPID_TUMORES_MALIGNOS_ MEX_2010.

  4. Warren S, Davis H. Studies on tumor metastasis: V. The metastases of carcinoma of the spleen. Am J Cancer 1934;21:517-533.

  5. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma. Analysis of 1000 autopsied cases. Cancer 1950;3(1):74-85.

  6. Nash DA, Sampson CC. Secondary carcinoma of the spleen. Its incidence in 544 cases and review of the literature. J Natl Med Asoc 1966;58(6):442-446.

  7. Lam KY, Tang V. Metastatic Tumors to the Spleen. A 25-Year Clinicopathologic Study. Arch Pathol Lab Med 2000;124(4):526-530.

  8. Kim JH, Choi YD, Lee JH, Nam JH, Juhng SW, Koh YS, et al. Solitary Splenic Metastases from Uterine Cervical Cancer: Case Reports and Review of the Literature. Korean J Pathol 2008;42(5):317-322.

  9. Gupta T, Nair N, Fuke P, Bedre G, Basu S, Shrivastava SK. Splenic metastases from cervical carcinoma: a case report. Int J Gynecol Cancer 2006;16(2):911-914.

  10. Pang LC. Solitary Recurrent Metastasis of Squamous Cell Carcinoma of the Uterine Cervix in the Spleen: Case Report. South Med J 2004;97(3):301-304.

  11. Piura B, Rabinovich A, Apel-Sarid L, Shaco-Levy R. Splenic metastasis from endometrial carcinoma: report of a case and review of literature. Arch Gynecol Obstet 2009;280(6):1001-1006.

  12. Andrei S, Preda C, Andrei A, Becheanu G, Herlea V, Lupescu I, et al. Isolated splenic metastasis of endometrial adenocarcinoma - a case report. Chirurgia (Bucur) 2011;106(6):833-837.

  13. Kara T, Kara O, Gedik GK, Sari O. Metástasis esplénica y abdominal multiples de un carcinoma de endometrio detectado con FDG. Rev Esp Med Nucl Imagen Mol 2012;31(1):31-33.

  14. Furukawa N. Solitary splenic metastasis of ovarian cancer. Arch Gynecol Obstet 2007;275(6):499-502.

  15. Farias-Eisner R, Braly P, Berek JS. Solitary Recurrent Metastasis of Epithelial Ovarian Cancer in the Spleen. Gynecol Oncol 1993;48(3):338-341.

  16. Compérat E, Bardier-Dupas A, Camparo P, Capron F, Charlotte F. Splenic Metastases: Clinicopathologic Presentation, Differential Diagnosis, and Pathogenesis. Arch Pathol Lab Med 2007;131(6):965-969.

  17. Kaza RK, Azar S, Al-Hawary MM, Francis IR. Primary and secondary neoplasms of the spleen. Cancer Imaging 2010;10(1):173-182.

  18. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: A review of the literature. Crit Rev Oncol Hematol 2008;66(1):10-20.

  19. Duk JM, Aalders JG, Fleuren GJ, Krans M, De Bruijn HWA. Tumor Markers CA 125, Squamous Cell Carcinoma Antigen, and Carcinoembryonic Antigen in Patients With Adenocarcinoma of the Uterine Cervix. Obstet Gynecol 1989;73(4):661-668.

  20. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Liver, Bladder, Cervical, and Gastric Cancers. Clin Chem 2010;56(6):e1-48.




2020     |     www.medigraphic.com